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PHARMACEUTICAL INNOVATION: DEFINITION, AND MECHANISMS FOR
REWARD
Hughes D
Bangor University, Bangor, UK
OBJECTIVES: To define the concept of pharmaceutical innovation, examine
whether it merits reward, and identify mechanisms for its incentivisation.
METHODS:Whether or not a medicine is innovative dependents on its novelty and
the benefits it generates. Novelty requires something new, original and perhaps
ingenious and is a necessary, but not sufficient, requirement for innovation. Novel
pharmaceutical attributes include: new target of pharmacological mechanism of
action, new chemical structure, improved formulation, improved pharmacokinet-
ics and efficient methods of production. Benefits depend on perspective. Whereas
a patient would value health-related quality of life, life expectancy, safety and
convenience, payers of healthcare (e.g. UK NHS) may legitimately value population
health and cost-effectiveness. A society might additionally value non-health ben-
efits such as attracting pharmaceutical company investment in skilled jobs, and
social responsibility (e.g. environment, neglected diseases). RESULTS: An effective
vaccine developed in the UK against malaria would be considered highly innova-
tive from a societal perspective, but not from an NHS perspective, as malaria does
not affect NHS patients. CONCLUSION: Health benefits to NHS patients are already
rewarded to (and in some cases beyond) the threshold for cost-effectiveness
(£30,000 per QALY). There is no incentive for paying an additional premium. How-
ever, where benefits of innovation to society exceed the costs, there is an argument
for reward. This should not be through price increases, but through taxation and
patent laws. The Patent Box, which will decrease the corporation tax to 10% on
profits from UK patents, is one such mechanism. Alternatively, a ‘value-based
patenting’ scheme might vary patent duration according to the benefits achieved,
as the clinical evidence matures from the time of licensing. This might benefit
patients through the earlier introduction of generics when branded products are
mediocre, reward genuinely innovative products, while still allowing the introduc-
tion of ‘me-toos’ to compete on price.
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A TYPOLOGY OF OUTCOMES FOR HEALTH RESEARCH
Levy A1, Sobolev B2, Briggs A3
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Measuring “outcomes” is at the heart of this Society’s mission and of efforts to
improve health and health care delivery. Despite this central role, there is no com-
mon agreed-upon definition as to what is meant by outcomes. For example, for
some commentators, outcomes refer uniquely to quality-of-life and survival of
individual patients; this thinking underlies the US Patient Centered Outcomes Re-
search Institute. For others, including those doing economic evaluation, outcomes
may refer to the average health benefit groups of patients. Yet others use “out-
comes” to refer to aspects of functioning of the health care system. This lack of
consistency does little to illuminate the challenges in equitably delivering timely,
high quality, and affordable health care. In this presentation, the authors present a
typology of outcomes for health research along with and relevant examples. At the
most granular level, endpoints in randomized trials are often clinical outcomes
which are characterized as immediately observable - “hard” - such as hospitaliza-
tion, death or functional status, or latent - “soft” - such as quality-of-life, pain, or
satisfaction. At the next level are health outcomes which are the results of care
delivered in actual practice and can be subdivided into: treatment outcomes which
reflect the intended and unintended medical consequences of undergoing therapy
and patient outcomes which reflect the impact on patients of undergoing care in
the real world. System outcomes can be thought of as the impact of delivering care
to a group of patients and are measures of the degree of functionality of the health
care system. At the highest level are societal outcomes, which measure the impact
of health on the wellbeing of society. Consensus as to what is meant by “outcomes”
would be an important step towards improving the quality of the discourse and
critical thinking in this area.
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OBJECTIVES: The objective of this study is to examine the potential impact of
recent reform in anti-rebate law of drugs in South Korea.METHODS: It has been an
old business practice that some doctors and pharmacists receive financial benefits
from pharmaceutical companies and distributors in exchange for business favors
in Korea. These kickbacks are considered ‘unethical and illegal drug rebates’. The
Korea Fair Trade Commission reckoned consumer damage caused by illegal re-
bates in the medicines market at about US$2.02 billion, accounting for about 20% of
total pharmaceutical sales in the year of 2007. There are a couple of reasons why
illegal drug rebate is so prevalent in Korea. First, the current drug pricing system
guarantees relatively good prices for generic products which local companies focus
on producing. Good prices tend to leave rooms for marketing and illegal rebates. On
top of that, there are lots of small scale suppliers relative to the pharmaceutical
market size of Korea. Fierce competitions among drug suppliers make them con-
centrate on marketing activities, often coupled with illegal rebates. Third, govern-
ment has no control over the visits by drug company representatives to doctors’
offices. In addition, almost no medical treatment guidelines which could effec-
tively regulate doctor’s prescription behavior exist. RESULTS: Previously, any ille-
gal marketing practice by drug companies led to criminal punishment of drug
companies alone, leaving doctors and pharmacists untouched. Under the new leg-
islation, punishment for illegal rebate is now extended to doctors and pharmacists.
By penalizing both rebate givers and receivers, it is hoped that the level of illegal
rebate can be disappeared or substantially reduced from the Korean market. How-
ever, we need to see what might happen in the real market practices from now on.
CONCLUSIONS: Remaining issues with this anti-rebate reform will be explored in
this study.
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ON-GOING MARKET ACCESS ADVICE A POSSIBLE SOLUTION TO HELP ENSURE
LONG-TERM SUCCESS IN POST-MARKETING CLINICAL STUDIES: CROSS
FUNCTIONAL TEAMS OR EXTERNAL CONSULTATION?
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OBJECTIVES:Manufacturers are under increasing pressure to conduct shorter clin-
ical trials in order to bring products to market as soon as possible and ensure
revenue maximisation before loss of exclusivity. At the same time, authorities
from markets across the globe have demonstrated increased interest in post-mar-
keting real-life clinical data in order to help make decisions with regards to reim-
bursement of drugs as well as their positioning in the treatment pathway.
METHODS: Manufacturers are spending increasing proportion of their budgets to
produce this post-marketing clinical data. It is important to ensure if the data that
is being produced is close to the needs of the payers. In majority of instances, it is
seen that the data being created is quite far from the expectations of authorities to
whose benefit it is being created. The data is typically considered for use in payer
discussions only at the end of the clinical study when little flexibility is possible in
the end-points and outcomes that will be demonstrated. Also, benefits such as
considering early data cuts to present on-going benefit of this long term data is not
usually seen. RESULTS: ; Market access, outcomes research and medical affairs
teams tend to function independently with very little collaboration as a result of
differing targets and budgets. This has made it difficult to have early payer-fo-
cussed input into clinical studies. This is particularly so if they are post-marketing
studies involving teams with lower focus on payer needs compared to peri-launch
market access teams. There is an increased need for greater cross-functional effort
on producing clinical data to ensure efficient use. CONCLUSIONS: Involving an
external market access agency that is able to advise on the production, analysis
and use of post-marketing clinical data is seen to be the solution to this issue.
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TELL ME WHO YOUR FRIENDS ARE: “PEERS” IN COMPARING HEALTH CARE
SYSTEMS
Carrera P
Ruprecht-Charles University of Heidelberg, Mannheim, Germany
Total health spending and its share in the social product have been staple indica-
tors in assessing and comparing health care systems. Comparison of health care
systems based on Euros and cents is limiting, however, since the health care sys-
tem is not an artifact of the economy. Institutions shape societal values on health
care leading to peculiarities even among health care systems that share traditions
in terms of health care financing and delivery. This paper presents a framework to
compare health care systems in a meaningful way that accounts for systemic
differences and similarities using the empirical technique cluster analysis. The
analysis will follow a three-step procedure. A review of the literature will be con-
ducted to identify major institutional indicators of any given health care system.
Cluster analysis will then be employed using these indicators based on data of
OECD member countries. Based on the isolated clusters using the “minimum de-
scription length” approach, “peer” health care systems will be identified and de-
scribed highlighting so-called leaders of the pack. At the heart of the performance
of every health care system is the extent to which it is able to respond to the desire
for a healthy life by members of society. This implies accounting for both efficiency,
which investigates the link between the link between health care resources and
health outcomes, and effectiveness, which assesses the achievement of goals
rather than choosing one over the other. Assessing health care systems against
peers and over time would not only set systems apart given their shared intent of
ensuring health by providing health care but may well engender learning and lead
to a race to the top.
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ENDOGENOUS COST-EFFECTIVENESS ANALYSIS IN HEALTH CARE
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Increased health care spending across developed nations, including the US, has put
pressure on both public and private payers. The current literature has attributed
this growth in spending as being largely due to technological change. To prioritize
adoption of new technologies, so called cost-effectiveness analysis has been used
as the main tool by third-party payers and, as a result, has generated perhaps the
largest sub-field within health economics. In this paper we argue utilization of
cost-effectiveness analysis is subject to a form of Lucas critique; the stated goals of
the policy will not materialize when those affected by it respond to it. In particular,
we stress that cost-effectiveness analysis by payers invariably reflects prices set by
producers rather than resource costs used to produce treatments. This implies that
the “costs” in cost-effectiveness assessments depend on endogenous markups
which are, in turn, influenced by demand factors of patients, doctors, and, most
importantly, the cost-effectiveness policy used by payers to translate prices to
adoption decisions. We argue this has two important implications. First, under
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endogenous cost-effectiveness analysis policies aimed at lowering spending may
actually raise it. Second, reimbursement policy based on endogenous cost-effec-
tiveness levels may lead to adoption of more inefficient treatments. Under the
standard conditions when producer costs are unobservable, we provide a test for
these conditions using data on technology appraisals in the UK 1999-2005.
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THE VALUES OF GENERAL PRACTITIONERS/FAMILY PHYSICIANS SHOULD BE
FOSTERED INTO OTHER CLINICIANS: A RESEARCH STUDY
Han-You X
Clinical institute, Workers’ hospital of Nanyang textile corporation, Nanyang city , China
OBJECTIVES: The paper is to improve the quality of life and health of the peoples of
the world by fostering and maintaining high standards of care in general practice/
family medicine and other clinicians. METHODS: By comparing the general prac-
titioners/family physicians with the clinicians of specialities, summarizing the
shortcomings of present health care services, the proposals for promoting health
care services around the world were suggested. RESULTS: The article initiates that
the values of general practice/family medicine should be fostered into other clini-
cians when all the clinicians take care of the patients in any conditions, critical or
ordinary, by adopting to the values of general practice/family medicine. While the
clinicians also take into account of their own specialities. CONCLUSIONS: In ap-
plying these proposals, a healthy world and high quality of life of the peoples of the
world will come soon! So the quality of life and health of the peoples of the world
can be promoted and enhanced.
Cardiovascular Disorders – Clinical Outcomes Studies
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EXPLORATIVE ANALYSIS ABOUT THE APPROPRIATENESS OF A GPS
LONGITUDINAL DATABASE ON EVALUATING ATYPICAL ANTIPSYCHOTICS IN
TERMS OF DRUGS ADVERSE EVENTS
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OBJECTIVES: The main objective of this study was to understand the appropriate-
ness of a GPs Longitudinal Database on exploring potential causal associations
among therapies and adverse events. We’ve focused on subjects treated with three
of the most widespread atypical antipsychotics drugs known as affecting patients’
lipidic profile and cardiovascular and diabetes risk.METHODS:Data were obtained
from CSD LPD, an Italian General Practitioner’s longitudinal database. Patients
with a first prescriptions of Aripiprazole, Olanzapine or Quetiapine during the pe-
riod January 2005 to December 2009 have been selected. For each patient, the first
prescription has been considered as the Index Date. The final study sample was
composed of patients that during the following three months had at least another
prescription of the same atypical antipsychotic. Patients have been followed-up for
a maximum of 12 months starting from three months after the Index Date.
RESULTS: Treatment groups were composed of 367 patients for Aripiprazole, 1825
patients for Olanzapine and 3088 patients for Quetiapine. The proportion of pa-
tients with an out of range value of Total Cholesterol and LDL was significantly
lower in Aripiprazole group. The same trend has been observed for the proportion
of patients with at least one recorded diagnosis of cardiovascular events and dia-
betes. The association between treatment and cardiovascular diagnosis presence
was still significant even when performing a multivariate logistic model adjusted
for age, gender and presence of a cardiovascular diagnosis during the year before
the Index Date (Odds Ratio Olanzapine VS. Aripiprazole: 1.76 [1.08 – 2.85]; Odds
Ratio Quetiapine versus Aripiprazole: 1.67 [1.03 – 2.70]). CONCLUSIONS: CSD LPD
database resulted to be appropriate in exploring potential causal associations
among treatments and potential adverse events both in terms of recorded diagno-
sis and in terms of recorded laboratory exams values even if, in this case, the
sample size was reduced.
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OBJECTIVES: To compare the prophylaxis patterns, incidence of venous thrombo-
embolism (VTE), major and minor bleeding and readmission over 90 days in hos-
pitalized medically ill patients.METHODS:A retrospective study (January 1, 2005 to
December 31, 2007) was conducted using a health insurance claims database. Eli-
gible patients were selected if they were continuously enrolled in their health plan
for at least 180 days prior to and 90 days following the index hospital discharge, for
which they were hospitalized with a medically ill diagnosis. Prophylaxis use was
defined as receiving low molecular weight heparin (LMWH) only, warfarin only,
unfractionated heparin (UFH) only, fondaparinux only, LMWH and warfarin, or
UFH and warfarin, from the index hospitalization date to 30 days after index hos-
pital discharge and before VTE events. Risk-adjusted venous thromboembolism
and major and minor bleeding events among patients with different thrombopro-
phylaxis patterns were compared. RESULTS: In patients who were identified as
medically ill (n12,077), 6,464 (53.52%) received anticoagulant therapy during their
hospitalization and until 30 days after discharge. Among these patients who re-
ceived prophylaxis, 2,137 (33.06%) received LMWH only, 693 (10.72%) received war-
farin only, 2168 (33.54%) received UFH only, 12 (0.19%) received fondaparinux only,
291 (4.50%) received LMWH and warfarin, and 325 (5.03%) received UFH and war-
farin. Among the 6 prophylaxis patterns, patients who received LMWH only were
associated with lower VTE (0.39% vs. 1.98%, p0.0001) and readmission rates (8.38%
vs. 13.68%, p0.0049) than those with LMWH and warfarin combination therapy. In
addition, the LMWH only group of patients had lower rates of major and minor
bleeding than the UFH and warfarin combination therapy group. CONCLUSIONS:
Despite existing guidelines, few medically ill patients receive anticoagulant pro-
phylaxis. Appropriate anticoagulant prophylaxis results in lower VTE event rates in
hospitalized medically ill patients.
PCV3
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OBJECTIVES: To assess the real-world rate of appropriate prophylaxis use for inci-
dences of venous thromboembolism (VTE), and major and minor bleeding in hos-
pitalized medically ill patients. METHODS: A retrospective study (January 01, 2005
to December 31, 2007) was conducted using a health insurance claims database.
Eligible patients were selected if they were continuously enrolled in their health
plan for at least 180 days prior to and 30 days following the index hospital discharge
date, for which they were hospitalized with a medically ill diagnosis. Prophylaxis
use was defined as receiving low molecular weight heparin (LMWH) only, warfarin
only, unfractionated heparin (UFH) only, fondaparinux only, LMWH and warfarin,
or UFH and warfarin, from the index hospitalization admission date to 30 days after
index hospital discharge, and before VTE events. Risk-adjusted VTE and major and
minor bleeding events among patients with different thromboprophylaxis pat-
terns were compared. RESULTS: In patients who were identified as medically ill
(n12,947), 6,949 (53.67%) received anticoagulant therapy during their hospitaliza-
tion and until 30 days after discharge. Among those patients who received prophy-
laxis, 2,295 (33.03%) received LMWH only, 752 (10.82%) received warfarin only, 2,313
(33.29%) received UFH only, 12 (0.17%) received fondaparinux only, 309 (4.45%)
received LMWH and warfarin, and 353 (5.08%) received UFH and warfarin. Com-
pared with patients who received LMWH only, patients who received the combi-
nation therapy of LMWH and warfarin had significantly more VTE events (1.14% vs.
0.32%, p0.0099) and higher readmission rates (6.11% vs. 3.05%, p0.0093), while
patients who received the combination therapy of UFH and warfarin had signifi-
cantly higher minor bleeding (11.70% vs. 6.06%, p0.0002) and readmission rates
(7.49% vs. 3.05%, p0.0001). CONCLUSIONS: Appropriate anticoagulant prophy-
laxis use results in lower VTE event rates as well as lower major and minor bleeding
rates in hospitalized medically ill patients. More effort is required to improve the
use of appropriate thromboprophylaxis.
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COMPARATIVE EFFICACY OF MAINTENANCE OF SINUS RHYTHM VERSUS RATE
CONTROL STRATEGIES IN THE TREATMENT OF ATRIAL FIBRILLATION –
SYSTEMATIC REVIEW AND META-ANALYSES
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OBJECTIVES: The aim of this study was to assess whether restoration and mainte-
nance of sinus rhythm is associated with clinically meaningful improvement in
patients with atrial fibrillation (AF) or atrial flutter (AFI). METHODS: Assessment
was based on randomized controlled trials (RCTs) identified by means of system-
atic review, carried out according to the Cochrane Collaboration guidelines. Studies
met the inclusion criteria if they directly compared two treatment strategies, i.e.
maintenance of sinus rhythm (MSR) including first generation antiarrhythmic
drugs (FGAAD; mainly amiodarone, sotalol, dizopiramide, propafenone, dofetilide,
flecainide) vs. rate control (RC) including pharmacologic agents (calcium channel
blockers, beta blockers, cardiac glycosides), with regard to clinically meaningful
endpoints. The most important medical databases (EMBASE, MEDLINE and CEN-
TRAL) were searched until January 2011. Two reviewers independently selected
trials, assessed their quality and extracted data. RESULTS: Eight RCTs directly
comparing MSR vs RC were identified and included. Meta-analysis of those studies
showed that significantly more patients assigned to MSR were in sinus rhythm at
the end of study as compared to RC strategy (RB  4.49 [2.49; 8.09]; NNT13-
37months  2 [2-4]). However, it did not lead to any benefit regarding clinically
meaningful endpoints. Comparison between both treatment strategies revealed no
statistically significant difference with respect to risk of overall mortality (RR 1.06
[0.96; 1.17]), cardiovascular mortality (RR 1.01 [0.88; 1.16]), stroke (RR 1.02 [0.82;
1.26]), systemic embolism (RR 0.78 [0.35; 1.71]), heart failure (RR 0.94 [0.80; 1.09])
or bleeding (RR 1.10 [0.65; 1.84]). CONCLUSIONS: In this analysis, restoration and
maintenance of sinus rhythm achieved with FGAAD was not associated with clin-
ically meaningful improvement in patients with AF or AFl. MSR strategy neither
improved survival nor decreased morbidity as compared to RC. The reevaluation of
current criteria of antiarrhythmic drug assessment should be considered.
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THROMBOEMBOLISMS WITH THROMBOPOIETIN RECEPTOR AGONISTS:
SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED
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